Citius Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $197.78 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Citius Pharmaceuticals Inc had its IPO on 2017-07-06 under the ticker symbol CTXR.
The company operates in the Healthcare sector and Biotechnology industry. Citius Pharmaceuticals Inc has a staff strength of 21 employees.
Shares of Citius Pharmaceuticals Inc opened at $1.25 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $1.22 - $1.32, and closed at $1.32.
This is a +6.45% increase from the previous day's closing price.
A total volume of 1,600,602 shares were traded at the close of the day’s session.
In the last one week, shares of Citius Pharmaceuticals Inc have increased by +18.92%.
Citius Pharmaceuticals Inc's Key Ratios
Citius Pharmaceuticals Inc has a market cap of $197.78 million, indicating a price to book ratio of 1.5048 and a price to sales ratio of 0.
In the last 12-months Citius Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-34398480. The EBITDA ratio measures Citius Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Citius Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -18.53% with a return of equity of -29.5%.
In Q1, Citius Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Citius Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.25 per share while it has a forward price to earnings multiple of 1.2887 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Citius Pharmaceuticals Inc’s profitability.
Citius Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.8708. Its price to sales ratio in the trailing 12-months stood at 0.
Citius Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $104.24 million
- Total Liabilities
- $6.21 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Citius Pharmaceuticals Inc ended 2023 with $104.24 million in total assets and $0 in total liabilities. Its intangible assets were valued at $104.24 million while shareholder equity stood at $91.21 million.
Citius Pharmaceuticals Inc ended 2023 with $5.85 million in deferred long-term liabilities, $6.21 million in other current liabilities, 146358.00 in common stock, $-143808137.00 in retained earnings and $9.35 million in goodwill. Its cash balance stood at $29.07 million and cash and short-term investments were $29.07 million. The company’s total short-term debt was $207,471 while long-term debt stood at $0.
Citius Pharmaceuticals Inc’s total current assets stands at $34.90 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.73 million and inventory worth $0.
In 2023, Citius Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Citius Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Citius Pharmaceuticals Inc stock is currently trading at $1.32 per share. It touched a 52-week high of $1.71 and a 52-week low of $1.71. Analysts tracking the stock have a 12-month average target price of $6.
Its 50-day moving average was $1.31 and 200-day moving average was $1.19 The short ratio stood at 5.33 indicating a short percent outstanding of 0%.
Around 841.5% of the company’s stock are held by insiders while 1148.1% are held by institutions.
Frequently Asked Questions About Citius Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.